J MOLNER
SpecialtyJ MOLNER is a specialty pharmaceutical company focused on Neurology, Metabolic, Cardiovascular.
Upcoming FDA Decisions
Full Calendar →J MOLNER's Key Drugs
J MOLNER's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
J MOLNER's Recent FDA Approvals
New NDA/BLA approvals for J MOLNER over the last two years — novel drugs only, excluding generics and label supplements.
J MOLNER's Therapeutic Areas
J MOLNER's approved drugs and pipeline span 5 therapeutic areas, led by Neurology and Metabolic, across 0 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
J MOLNER's Top Competitors
J MOLNER's closest competitors by therapeutic-area and drug-target overlap include Takeda, Novo Nordisk, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
J MOLNER Pipeline Snapshot
Active clinical trials for J MOLNER across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Neurology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1984-03-30
- Latest
- 2022-07-21
- Applications
- 8